Biotech and Breakthroughs in Immuno-Oncology

被引：0

作者：

Bockman, Jeffrey M. ^{[1
]}

机构：

[1] Cello Hlth Bio Consulting, 25-B Hanover Rd,Suite 320, Florham Pk, NJ 07932 USA

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2020年 / 47卷 / 04期

关键词：

Immunotherapy; Immuno-oncology; Checkpoint inhibitors; Tumor microenvironment; Urologic oncology;

D O I：

10.1016/j.ucl.2020.07.006

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The age of immuno-oncology has ushered in a rush within the biopharmaceutical industry. This intense focus has been characterized as a frenzy or overhyped, but represents a substantial investment in new products that hope to harness the immune system against cancer. Such agents include next-generation checkpoint antagonists, immune costimulatory agonists, and a diverse array of novel mechanisms of action and therapeutic modalities targeting immune cell types and the interplay of the host and tumor at the immune synapse. This article surveys the clinical development and investment activity with Immuno-Oncology, specifically prostate, kidney, and bladder cancers. © 2020 Elsevier Inc.

引用

页码：511 / 521

页数：11